Table 1 Clinic-pathological characteristics of the study participants according to HER2 status at initial diagnosis (1A) and when metastatic (1B) (N:491).
From: The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Characteristics | HER2-negative, 102 pts [N (%)] | HER2-positive, 389 pts [N (%)] | p-value |
|---|---|---|---|
Section A. Characteristic of BC at initial diagnosis | |||
Age | |||
≤ 65 | 96 (94.1%) | 354 (91%) | 0.37 |
> 65 | 6 (5.9%) | 35 (9%) | |
Histological subtype | |||
Ductal | 82 (80.4%) | 340 (87.4%) | 0.11 |
Lobular | 7 (6.8%) | 18 (4.6%) | |
Other | 13 (12.8%) | 31 (8.0%) | |
Estrogen Receptor | |||
Positive | 82 (80.4%) | 232 (59.6%) | < 0.0001 |
Negative | 20 (19.6%) | 157 (40.4%) | |
Progesterone Receptor | |||
Positive | 58 (56.9%) | 162 (41.6%) | 0.006 |
Negative | 44 (43.1%) | 227 (58.4%) | |
Neo-/adjuvant treatment | |||
Yes | 91 (89.2%) | 350 (90%) | 0.82 |
No | 11 (10.8%) | 39 (10%) | |
Neo-/adjuvant trastuzumab | |||
Yes | 0 | 259 (66.6%) | < 0.001 |
No | 102 (100%) | 130 (33.4%) | |
Section B. Characteristics of BC when metastatic | |||
IHC Subtype | |||
TP | 54 (53.0%) | 158 (40.6%) | |
ER or PgR positive | 28 (27.4%) | 74 (19.0%) | < 0.0001 |
ER and PgR negative | 20 (19.6%) | 157 (40.4%) | |
Visceral metastases | |||
Yes | 77 (75.5%) | 254 (65.3%) | 0.05 |
No | 25 (24.5%) | 135 (34.7%) | |
Bone metastases only | |||
Yes | 4 (3.9%) | 24 (6.2%) | 0.38 |
No | 98 (96.1%) | 365 (93.8%) | |
Brain metastases | |||
Yes | 15 (14.7%) | 104 (26.7%) | 0.01 |
No | 87 (85.3%) | 285 (73.3%) | |
Number of metastatic sites | |||
1 | 72 (70.7%) | 275 (70.7%) | |
2 | 17 (16.6%) | 72 (18.5%) | 0.81 |
> 2 | 13 (12.7%) | 42 (10.8%) | |
Disease Free Interval | |||
< 3 years | 24 (23.5%) | 182 (46.7%) | < 0.0001 |
≥ 3 years | 75 (73.5%) | 193 (49.6%) | |
